AN ACT concerning State government. 1

Be it enacted by the People of the State of Illinois, 2 represented in the General Assembly: 3

- Section 5. The Department of Public Health Powers and 4 5 Duties Law of the Civil Administrative Code of Illinois is amended by adding Section 2310-730 as follows: 6
- 7 (20 ILCS 2310/2310-730 new)
- Sec. 2310-730. Diversity in clinical trials. 8
- 9 (a) As used in this Section, "underrepresented community" or "underrepresented demographic group" means a community or 10 demographic group that is more likely to be historically 11 12 marginalized and less likely to be included in research and clinical trials represented by race, ethnicity, sex, sexual 13 14 orientation, socioeconomic status, age, and geographic location. 15
 - (b) The Department of Public Health shall adopt rules requiring any State entity or hospital that receives funding from the National Institutes of Health for the purpose of conducting clinical trials of drugs or medical devices to:
- (1) adopt a policy that will result in the 20 21 identification and recruitment of persons who are members of underrepresented demographic groups to participate in 22
- the clinical trials and that: 2.3

16

17

18

19

1	(A) includes specific strategies for trial
2	enrollment and retention of diverse participants,
3	including, but not limited to, site location and
4	access, sustained community engagement, and reducing
5	burdens due to trial design or conduct, as
6	appropriate; and
7	(B) uses strategies recommended by the United
8	States Food and Drug Administration to identify and
9	recruit those persons to participate in the clinical
10	<u>trials;</u>
11	(2) provide information to trial participants in
12	languages other than English in accordance with current
13	<pre>federal requirements;</pre>
14	(3) provide translation services or bilingual staff
15	for trial recruitment and consent processes;
16	(4) provide culturally specific recruitment materials
17	alongside general enrollment materials; and
18	(5) provide remote consent options when not prohibited
19	by the granting entity or federal regulations.
20	(c) The Department, in consultation the University of
21	Illinois Cancer Center, with academic organizations,
22	community-based organizations, and other relevant research
23	organizations, shall analyze and provide recommendations or
24	the following:
25	(1) the demographic groups and populations that are
26	currently represented and underrepresented in clinical

1	trials in Illinois, including representation of groups
2	based on their geographic location;
3	(2) the barriers that prevent persons who are members
4	of underrepresented demographic groups from participating
5	in clinical trials in Illinois, including barriers related
6	to transportation; and
7	(3) approaches for how clinical trials can
8	successfully partner with community-based organizations
9	and others to provide outreach to underrepresented
10	communities.
11	By July 1, 2025, the Department shall report to the
12	General Assembly the results of the analysis required under
13	this subsection and any recommendations to increase diversity
14	and reduce barriers for participants in clinical trials.
15	(d) The Department shall review the most recent quidance
16	on race and ethnicity data collection in clinical trials
17	published by the United States Food and Drug Administration
18	and establish, using existing infrastructure and tools, a
19	program to encourage participation in clinical trials of drugs
20	and medical devices by persons who are members of demographic
21	groups that are underrepresented in such clinical trials. The
22	<pre>program must include, without limitation:</pre>
23	(1) collaboration with medical facilities, health
24	authorities and other local governmental entities,
25	nonprofit organizations, and scientific investigators and
26	institutions that are performing research relating to

1	drugs or medical devices to assist those investigators and
2	institutions in identifying and recruiting persons who are
3	members of underrepresented demographic groups to
4	participate in clinical trials; and
5	(2) the establishment and maintenance of an Internet
6	website that:
7	(A) provides information concerning methods
8	recognized by the United States Food and Drug
9	Administration for identifying and recruiting persons
10	who are members of underrepresented demographic groups
11	to participate in clinical trials; and
12	(B) contains links to Internet websites maintained
13	by medical facilities, health authorities and other
14	local governmental entities, nonprofit organizations,
15	and scientific investigators and institutions that are
16	performing research relating to drugs or medical
17	devices in this State.
18	The Department may apply for grants from any source,
19	including, without limitation, the Federal Government, to fund
20	the requirements of this Section.